380 results about "Disease status" patented technology

Arrays containing a transcriptome of a diseased tissue and methods of using the arrays for diagnosis, prognosis, screening, and identification of disease are provided herein. The transcriptome arrays from diseased tissue are useful for diagnosis of a disease by analysis of the genetic profile of a tissue sample specific to a disease state. The genetic profiles are then correlated with data on the effectiveness of specific therapeutic agents. Correlating expression profiles to the effectiveness of therapeutic agents provides a way to screen and select further patients predicted to respond to those therapeutic agents, thereby minimizing needless exposure to ineffective therapy.

The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2—R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb, SO2NR7R8, CONR7R8, NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4 hydrocarbyl; X1 is O, S or NRc and X2 is ═O, ═S or ═NRc; R7 is selected from hydrogen and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; R8 is selected from R7 and carbocyclic and heterocyclic groups having from 3 to 12 ring members; R9 is selected from R8, COR8 and SO2R8; or NR7R8 or NR7R9 may each form a heterocyclic group having from 5 to 12 ring members; but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

A method and system of differentially manipulating cells where the cells, suspended in a fluid, are irradiated with substantially monochromatic light. A Raman data set is obtained from the irradiated cells and where the data set is characteristic of a disease status. The data set is assessed to identify diseased cells. A Raman chemical image of the irradiated cells is also obtained. Based on the assessment and the Raman chemical image, the fluid in which the cells are suspended is differentially manipulated. The diseased cells are directed to a first location and other non-diseased cells are directed to a second location as part of the differential manipulation. The diseased cells may be treated with a physical stress, a chemical stress, and a biological stress and then returned to a patient from whom the diseased cells were obtained prior to the irradiation.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and / or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and / or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and / or determine efficacy of a treatment modality.

A system and method of hyperspectral chemical imaging (fluorescence or absorption based) to provide an automated approach for a more detailed analysis of disease status of a biological sample. When a biological sample is labeled with a fluorescent or light-absorbing contrast-enhancing agent, interactions between the contrast-enhancing agent and one or more constituents (or cellular components) of the biological sample may be manifested through spectral contents of a plurality of regions in a hyperspectral chemical image of the sample. Observations of such manifestations through analysis of corresponding spectral contents may greatly assist a user (e.g., a pathologist) in detecting and differentiating diseased portions of the stained sample. Hyperspectral chemical imaging may allow to identify multiple cellular components within a biological sample and to image their distribution within the sample, thereby assisting a pathologist to successfully and more accurately identify diseased portion(s) of the sample for further diagnosis and treatment.